Search This Blog

Thursday, September 7, 2023

Trump Calls On Big Pharma To Disclose All Vaccine Side Effect Data

 by Tom Ozimek via The Epoch Times,

Former President Donald Trump told former Michigan gubernatorial candidate Tudor Dixon in a recent conversation on her podcast that pharmaceutical companies have an "obligation to be honest" about vaccine side effects and should disclose all relevant data on vaccine harms.

President Trump and Ms. Dixon discussed a range of issues in an episode on the Tudor Dixon Podcast last week, ranging from corruption allegations against President Joe Biden to claims of weaponization of federal agencies against the former president.

"This is the most corrupt president in history," President Trump alleged, referring to his successor in the Oval Office.

"And the most incompetent at the same time. It's pretty incredible," President Trump added, insisting that the various criminal charges that have been levied against him are attempts to interfere in the 2024 election.

At one point in the discussion, Ms. Dixon asked about President Biden’s announcement to fund a new COVID-19 vaccine.

“He wants everyone to get this vaccine,” Ms. Dixon said.

“And we’re hearing about a lot of complaints from vaccine injured. To say a lot is an understatement."

There have been reports linking spike protein-based COVID-19 vaccines to skin problems, a dull ringing in the ears known as tinnitusvisual impairmentsblood clotting, and even death.

Studies have also revealed a number of other issues affecting vaccinated children. For example, one recent study, published in the journal Frontiers in Immunology, shows that the mRNA-based vaccine for COVID-19 reduced children's immune responses to other infections, making them more prone to getting sick after coming into contact with other pathogens.

Another study published by Circulation showed that some children who experienced heart inflammation after COVID-19 vaccination had scarring on their hearts months later.

'We’re All In This Together'

Ms. Dixon then asked President Trump about vaccine data transparency, citing reports of various adverse events, including heart inflammation and blood clots.

"Numerous pharmaceutical companies have refused to release their data on vaccine side effects," she said.

"But we’ve seen cases of myocarditis, blood clots, and heart attacks; they’re all increasing. The research has never been released.”

She then asked if President Trump would “demand that the vaccine companies, that the pharmaceutical companies release their vaccine data to the public so that we can see what they’re actually seeing about the side effects of this vaccine?”

President Trump replied by saying that pharmaceutical companies "should do that," adding that "we’re all in this together, and they should be doing that."

In context of President Biden's remarks about funding a new COVID-19 vaccine, the former president said that "anything new has got to be looked at very carefully."

He then reiterated the point that pharmaceutical companies should release any data on vaccine side effects.

"They should be made public immediately. People should understand that, and they should know what research is showing," President Trump said.

Ms. Dixon then noted that under the Public Readiness and Emergency Preparedness Act, pharmaceutical companies are shielded from liability from vaccine injuries until December 2024.

"So once that sunsets, then they can be held liable for any type of vaccine injuries, will you tell these companies that they must be honest about what has happened with this vaccine?" Ms. Dixon asked.

President Trump replied by saying that the companies would be wrong to withhold any information on vaccine harms.

“They have to be honest with the numbers, the facts, and they have an obligation to be honest,” he said, “And if they are going to hold back, that means they’re holding back something that’s not good.”

“We’ll stand for them in many ways,” President Trump said of people who suffered vaccine injuries.

Meanwhile, the Food and Drug Administration (FDA) has been ordered to accelerate the pace at which it releases to the public data it relied on to license COVID-19 vaccines.

Watch the full interview below:

COVID-19 Vaccine Trial Data

In May, a federal judge in Texas ruled that the FDA must hurry up with disclosing data that underpinned its decision to license COVID-19 vaccines, ordering all documents to be made public by mid-2025 rather than, as the FDA wanted, over the course of about 23.5 years.

"Democracy dies behind closed doors," is how U.S. District Judge Mark Pittman opened his order (pdf), which requires the FDA to produce the data on Moderna's and Pfizer's COVID-19 vaccines at an average rate of at least 180,000 pages per month.

The FDA had argued it would be "impractical" to release the estimated 4.8 million pages at more than between 1,000 and 16,000 pages per month: a rate which would see packets of information released for at least 23.5 years.

While the judge noted in his order that the court recognizes the FDA's limited resources dedicated to freedom of information requests (FOIA), he stated that "the number of resources an agency dedicates to such requests does not dictate the bounds of an individual's FOIA rights."

"Instead, the Court must ensure that the fullest possible disclosure of the information sought is timely provided—as 'stale information is of little value,'" Mr. Pittman wrote.

Confidence in the FDA over COVID-19 vaccine approvals was shaken by the disclosure that regulators sped up the approval of Pfizer's vaccine in order to facilitate mandates.

The Centers for Disease Control and Prevention (CDC) continues to recommend that people of all ages receive a COVID-19 vaccine, despite the risk of heart inflammation and other side effects.

https://www.zerohedge.com/political/trump-calls-big-pharma-disclose-all-vaccine-side-effect-data

iCoreConnect, Inc. Acquires Assets of Preferred Dental Services

  iCoreConnect, Inc., (NASDAQ: ICCT), (“iCore” or the “Company”), a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, today announced the acquisition of the assets of Preferred Dental Services (“PDS”). Preferred Dental Services is a provider of dental billing, claims, and insurance management services.

https://finance.yahoo.com/news/icoreconnect-inc-acquires-assets-preferred-213000934.html

Krystal started at Buy by Berenberg

 Target $154

https://finviz.com/quote.ashx?t=KRYS&ty=c&ta=1&p=d

Kenvue started at Buy by Canaccord

 Target $28

https://finviz.com/quote.ashx?t=KVUE&ty=c&ta=1&p=d

Why Shares of Neogen Are Slumping

 Shares of Neogen Corporation (NEOG -13.18%) were down more than 16% for the week, according to data provided by S&P Global Market Intelligence. The healthcare company, which specializes in food and animal safety solutions, saw its stock close last week at $23.33. It then fell to as low as $20.22 on Thursday after Neogen released preliminary fiscal 2024 first-quarter numbers. The stock is still up more than 27% this year.

The company announced, in an investor presentation at the Wells Fargo 2023 Healthcare Conference in Boston, that it is expecting fiscal 2024 first-quarter revenue to be slightly below expectations.

Neogen CEO John Adent said that the company's revenue "came in a little lighter than we'd thought." Animal safety revenue is expected to fall by high-single-digit percentages, due to softer genomic sales. While its legacy food safety business was expected to rise in the mid-single digits, the company saw revenue flat from its 3M food safety business mainly due to a weakness in business in China and in Asia overall, tied to supply constraints. 

The company traditionally has had a slow first quarter, so the lower numbers aren't a huge cause for concern. Neogen had a better fourth quarter. While revenue was reported as $241.8 million, up 72.6% year over year in the fourth quarter, net income was $5.6 million, compared to $14.9 million in the same period last year. Earnings per share (EPS) was $0.03 compared to $0.14 in the fourth quarter of fiscal 2022. The company said it is waiting for business to pick up once its clients run though what is considered a backlog of inventory.

https://www.fool.com/investing/2023/09/07/why-shares-of-neogen-are-slumping-this-week/

'Jill Biden tests negative for COVID - White House'

 U.S. first lady Jill Biden tested negative for COVID-19 on Thursday, the White House said.

The first lady, who tested positive for COVID on Monday, experienced mild symptoms and remained in Delaware when President Joe Biden returned to Washington on Monday evening, the White House has said.

The president, who has tested negative several times since Monday, is due to travel to Group of 20 summit in India on Thursday.

https://news.yahoo.com/jill-biden-tests-negative-covid-195401284.html

Israeli scientists create model of human embryo without eggs or sperm

 Scientists in Israel have created a model of a human embryo from stem cells in the laboratory, without using sperm, eggs or a womb, offering a unique glimpse into the early stages of embryonic development.

The model resembles an embryo at day 14, when it acquires internal structures but before it lays down the foundations for body organs, according to the team at Israel's Weizmann Institute of Science.

The scientists' work was published in the journal Nature on Wednesday after a pre-print came out in June, during the International Society for Stem Cell Research (ISSCR)'s annual meeting in Boston.

The Israeli team emphasised that they were a long way from being able to create an embryo from scratch.

"The question is, when does an embryo model become considered an embryo? When that happens, we know the regulations. At the moment we are really, really far off from that point," said team leader Jacob Hanna.

However, they said the work could open the door to new ways to test the effect of drugs on pregnancies, better understand miscarriages and genetic diseases, and perhaps even to grow transplant tissues and organs.

"They are not identical. There are differences from human embryos, but still, this is the first time, if you open an atlas or a textbook, you can say - yeah I can really see the similarity between them," said Hanna.

He said his team took stem cells derived from adult human skin cells, as well as others cultured in the lab, then reverted the cells to an early state with the potential to develop into different cell types.

They then manipulated them to form the basis of something structurally resembling an embryo. It is not an actual or synthetic embryo - a term criticised by the ISSCR and other scientists - rather a model showing how one works.

"In about 1 percent of the aggregates we can see that the cells start differentiating correctly, migrating and sorting themselves into the correct structure, and the farthest we could get is day 14 in human embryo development," he said.

Their next goal, Hanna said, is to advance to day 21 and also reach a threshold of a 50% success rate.

Magdalena Żernicka-Goetz, a professor of development and stem cells at the University of Cambridge, said the study joins six other similar human embryo-like models published from teams around the world this year, including from her lab.

"None of these models fully recapitulate natural human development but each adds to ways in which many aspects of human development can now be studied experimentally," she said.

The study raises some ethical questions over the possibility of potential future manipulation in human embryo development, Hanna and others noted. He drew a comparison to nuclear physics, however, arguing that you should not stop all research in that field because somebody might choose to make a nuclear bomb.

It is important to engage and fully inform the public, he said, with "nothing done in the shadows".

https://news.yahoo.com/israeli-scientists-create-model-human-162323174.html